We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


Highly Advanced AI Model Precisely Detects COVID-19 by Analyzing Lung Images

Researchers have designed and validated an image-based detection of COVID-19 with the aid of artificial intelligence (AI) models by using a model to automatically collect imaging data from the lung lobes. This data was then analyzed to yield features as potential diagnostic biomarkers for COVID-19. More...
13 Aug 2021

Unsupervised AI Model Accurately Predicts COVID-19 Patient's Survival Based on Chest CT Exams

An "unsupervised" artificial intelligence (AI) model, or one trained without image annotations, can accurately predict the survival of COVID-19 patients on the basis of their chest computed tomography (CT) exams. More...
08 Aug 2021

Regeneron’s Investigational Antibody Cocktail Granted FDA EUA for Preventing COVID-19

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) has announced that the US Food and Drug Administration (FDA) has updated the Emergency Use Authorization (EUA) for its investigational COVID-19 antibody cocktail REGEN-COV (casirivimab and imdevimab). More...
08 Aug 2021

Highly Potent Mini-Antibodies '1000 Times' Better at Neutralizing SARS-CoV-2 Could Be Promising Agents to Treat COVID-19

Researchers have developed mini-antibodies that efficiently block the SARS-CoV-2 virus and its dangerous new variants. More...
06 Aug 2021

Eli Lilly and Incyte’s Baricitinib Reduces Deaths among COVID-19 Patients Receiving Invasive Mechanical Ventilation

New data from a Phase 3 COV-BARRIER sub-study indicates one death prevented for every six baricitinib-treated COVID-19 patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) as compared to placebo. More...
06 Aug 2021

Follow-Up Research Provides Key Insights into COVID-19 Vaccine Efficacy

Large-scale follow-up studies conducted on those vaccinated by the Pfizer-BioNTech COVID-19 vaccine shed new light on how long antibodies last, effects on types of patients, and effectiveness against the Delta variant. More...
03 Aug 2021
Image: Baricitinib (Photo courtesy of Eli Lilly and Company)

Eli Lilly and Incyte’s Baricitinib Receives FDA EUA for Use as Monotherapy in Hospitalized COVID-19 Patients Requiring Oxygen

The US Food and Drug Administration (FDA) has broadened the emergency use authorization (EUA) for baricitinib, a JAK1/JAK2 inhibitor licensed to Eli Lilly and Company (Indianapolis, Ind, USA) from Incyte (Wilmington, DE, USA), to allow for treatment with or without Gilead Sciences’ (Foster City, CA, USA) antiviral drug remdesivir. More...
30 Jul 2021
Copyright © 2000-2021 Globetech Media. All rights reserved.